Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
🏥⭐⭐⭐⭐ Strong — Supported by multiple RCTs and meta-analyses, especially for colorectal and pancreatic cancers.Turmeric extractDiferuloylmethaneTheracurmin (bioavailable form)
Forms: Curcumin capsules (500–2000 mg, with piperine or Theracurmin)
Educational only, not medical advice. OncoForge makes no claim that Curcumin / Theracurmin treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Well-studied turmeric extract that shuts down NF-κB/STAT3 inflammation, nudges tumor cells into apoptosis, and reduces VEGF/MMPs. Bioavailability is the bottleneck—formulations like Theracurmin improve exposure. Human trials show signals across several cancers and for chemo-sensitization.
Curcumin, a turmeric-derived polyphenol, inhibits NF-κB and STAT3 pathways, reducing inflammation-driven tumor growth and metastasis. It downregulates anti-apoptotic proteins (Bcl-2, Bcl-xL), upregulates pro-apoptotic Bax, and activates caspases, inducing apoptosis. Curcumin resensitizes tumor cells to platinum-based chemotherapy by inhibiting ABC transporters and DNA repair pathways. It also suppresses VEGF, MMP-2, and MMP-9, inhibiting angiogenesis, and modulates PI3K/Akt/mTOR to limit cell proliferation.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
NF-κB ↓: Avoid stacking with other strong NF-κB inhibitors without rationale.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
Risk categories
Gi Upset MildHepatotoxicity Risk MildPregnancy Avoid
Potential interactions
CYP3A4/P-gp substrates (e.g., TKIs, chemo)MonitorModerateTheoreticalMay alter levels; pharmacist review.
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
Biomolecules · Nov 2022 · literature review (PubMed search, accessed 18 June 2022)
Curcuminnon-small cell lung cancer (NSCLC)lung carcinomalung neoplasms
This paper is a literature review that collected reports on curcumin and its analogs in non-small cell lung cancer (PubMed search accessed 18 June 2022). The authors summarize reported anti-NSCLC mechanisms, review combinations of curcumin with chemotherapeutic agents, and used Discovery Studio to speculate on interactions with molecular targets. They note that many studies report anticancer effects of curcumin/analogs but that results of clinical trials have been inconsistent. The review concludes that curcumin and its analogs may be promising therapeutic agents or adjuvants for lung carcinoma despite existing challenges.
Studied with: chemotherapeutic agents.
Key findings
Advances in NSCLC therapy (chemoradiotherapy, targeted therapy, immunotherapy) have improved survival but overall recovery and survival rates remain low.
There is an urgent need for novel NSCLC drugs or combination therapies with less toxicity.
Anticancer effectiveness of curcumin and some curcumin analogs has been reported in many studies.
Results from clinical trials of curcumin in NSCLC have been inconsistent.
The authors collected recent reports on anti-NSCLC mechanisms of curcumin/analogs and their combinations with chemotherapeutic agents via PubMed.
The authors used Discovery Studio to speculate on interplay between curcumin and various molecular targets relevant to NSCLC.
Despite challenges, curcumin/curcumin analogs may serve as promising therapeutic agents or adjuvants for lung carcinoma treatment.
Limitations: This article is a literature review rather than original experimental work.; The abstract states that clinical trial results are inconsistent, limiting clinical conclusions.; The interaction analysis using Discovery Studio is speculative/in silico and not experimentally validated in this paper.; Search was limited to PubMed reports accessed up to 18 June 2022 (date-limited review)..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Curcumin / Theracurmin's evidence base, and anything that's been retracted.
Evidence at a glance: Curcumin / Theracurmin by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
No human studies yet · No numeric effect sizes reported · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Curcumin / Theracurmin depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Ranges seen in adjunct / practice use: 500–8000 mg (po) Divided into 2–3 doses daily. Oncology adjunct: 1000–4000 mg/day (enhanced forms like Theracurmin for better absorption); up to 8000 mg/day in trials., No Rx required. Use bioavailable forms (e.g., with piperine/Theracurmin); take with meals. Clinician oversight for oncology; monitor LFTs at high doses..
Curcumin / Theracurmin is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.